Covid Vaccine Adverse Effects Research - List of Studies

Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2

Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults

Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex

A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against COVID-19

Observational Findings of PULS Cardiac Test Findings for Inflammatory Markers in Patients Receiving mRNA Vaccines

Worse Than the Disease? Reviewing Some Possible Unintended Consequences of the mRNA Vaccines Against COVID-19

Neuropathic symptoms with SARS-CoV-2 vaccination

Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System

The presence of serum anti-SARS-CoV-2 IgA appears toprotect primary health care workers from COVID-19

Persistent Cardiac MRI Findings in a Cohort of Adolescents with post COVID-19 mRNA vaccine myopericarditis

Myocarditis following mRNA vaccination against SARS-CoV-2, a case series

Evaluating the relationship between myocarditis and mRNA vaccination

COVID-19 vaccine-induced myocarditis: Case report with literature review

Myocarditis in the Setting of Recent COVID-19 Vaccination

Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination

MYOCARDITIS LINKED TO PFIZER-BIONTECH COVID-19 VACCINE

Autopsy Histopathologic Cardiac Findings in Two Adolescents Following the Second COVID-19 Vaccine Dose

Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis

Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types

Fulminant myocarditis after the second dose of COVID‐19 mRNA vaccination

Acute myocarditis associated with COVID-19 vaccination: A case report

A report of two cases of myocarditis following mRNA coronavirus disease 2019 vaccination

Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military

Post RNA-based COVID vaccines myocarditis: Proposed mechanisms

Post-mRNA COVID-19 Vaccination Myocarditis

Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children

Myocarditis and pericarditis after vaccination for COVID‐19

COVID-19 vaccine-induced myocarditis: Case report with literature review

Myocarditis following COVID-19 vaccination – A case series

Myocarditis following COVID-19 vaccination

Autopsy Histopathologic Cardiac Findings in Two Adolescents Following the Second COVID-19 Vaccine Dose

Considerations for Producing mRNA Vaccines for Clinical Trials

The promise of mRNA vaccines: a biotech and industrial perspective

A Comparison of Plasmid DNA and mRNA as Vaccine Technologies

Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens

Progresses towards safe and efficient gene therapy vectors

mRNA Leapfrogs DNA to Show Promise for Therapeutic Gene Transfer

Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections

A novel, disruptive vaccination technology

Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting

COVID 19 Vaccines: Should we fear ADE?

The tangled history of mRNA vaccines

Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study

COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines

The Promise of mRNA Vaccines

Long-term course of humoral and cellular immune responses in outpatients after SARS-CoV-2 infection

SARS-CoV-2 vaccine-associated-tinnitus: A review

‘Leaky’ Vaccines Can Produce Stronger Versions of Viruses

Longitudinal extensive transverse myelitis following ChAdOx1 nCOV-19 vaccine: a case report

NIH funding for vaccine readiness before the COVID-19 pandemic

Measurement of SARS-CoV-2 RNA in wastewater tracks community infection dynamics

Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines

FACT SHEET FOR RECIPIENTS AND CAREGIVERS EMERGENCY USE AUTHORIZATION (EUA) OF THE MODERNA COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19) IN INDIVIDUALS 18 YEARS OF AGE AND OLDER

Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers

(STUDY) Why so many vaccinated people are getting sick: Antibody Dependent Enhancement (ADE)

PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Call to Action for Dengue Vaccine Failure

Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine

The spike protein of SARS-CoV–a target for vaccine and therapeutic development

Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection

The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection

Protection and waning of natural and hybrid COVID-19 immunity

Stabilizing the closed SARS-CoV-2 spike trimer

Why are we vaccinating children against COVID-19?

PAMAM dendrimers as promising nanocarriers for RNAi therapeutics

mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status

Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study

MIT & Harvard Study Suggests mRNA Vaccine Might Permanently Alter DNA After All

Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape

Engineers design programmable RNA vaccines

Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro

Protective immunity after recovery from SAR-CoV-2 infection

Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTechmRNA COVID‐19 vaccine

A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection

Shell Game? There remains no FDA approved COVID vaccine in the United States

Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

Without these lipid shells, there would be no mRNA vaccines for COVID-19

High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines

Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial

Post COVID-19 vaccination neuromyelitis optical spectrum disorder: Case report & MRI findings

This ‘super antibody’ for COVID fights off multiple coronaviruses

Understanding mRNA COVID-19 Vaccines

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections

Neuromyelitis Optica in a Healthy Female After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine

Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients

Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies

Developing mRNA-vaccine technologies

Necessity of COVID-19 vaccination in previously infected individuals

Nonarteritic Anterior Ischemic Optic Neuropathy following COVID-19 Vaccination: Consequence or Coincidence

Long-term cardiovascular outcomes of COVID-19

COVID-19 Vaccine and Ovarian Reserve

Long-Term Persistence of IgG Antibodies in recovered COVID-19 individuals at 18 months and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response

Vaccination with messenger RNA (mRNA)

Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar

Increased risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated individual

COVID-19 infections increase risk of heart conditions up to a year later, study finds

Safety of COVID-19 vaccines administered in the EU: Should we be concerned?

Antibody Evolution after SARS-CoV-2 mRNA Vaccination

Chemistry of Lipid Nanoparticles for RNA Delivery

Discrete Immune Response Signature to SARS-CoV-2 mRNA Vaccination Versus Infection

Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees

A Late Presentation of COVID-19 Vaccine-Induced Myocarditis

Alkylative damage of mRNA leads to ribosome stalling and rescue by trans translation in bacteria

Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19

COVID-19 Vaccines & Fetal Cell Lines

Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees

U.S. Government Gain-of-Function Deliberative Process and Research Funding Pause on Selected Gain-of-Function Research Involving Influenza, MERS, and SARS Viruses

Risk of myocarditis following sequential COVID-19 vaccinations by age and sex

Brain death in a vaccinated patient with COVID-19 infection

Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination?

mRNA vaccine delivery using lipid nanoparticles

Equivalency of Protection from Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic Review and Pooled Analysis

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

COVID‐19 vaccine anaphylaxis: PEG or not?

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Advances in mRNA Vaccines for Infectious Diseases

Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals

mRNA vaccine-induced SARS-CoV-2-specific T cells recognize B.1.1.7 and B.1.351 variants but differ in longevity and homing properties depending on prior infection status